Artículos por temáticas

Long term understanding of study information in research participants with Parkinson's disease.

Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY.

Parkinsonism Relat Disord. 2010 Jan;16(1):60-3. doi: 10.1016/j.parkreldis.2009.05.007.

Is there muscular weakness in Parkinson's disease?

Cano-de-la-Cuerda R, Pérez-de-Heredia M, Miangolarra-Page JC, Muñoz-Hellín E, Fernández-de-Las-Peñas C.

Am J Phys Med Rehabil. 2010 Jan;89(1):70-6. doi: 10.1097/PHM.0b013e3181a9ed9b. Review.

[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL.

Parkinsonism Relat Disord. 2010 Jan;16(1):57-9. doi: 10.1016/j.parkreldis.2009.05.005.

Visual-spatial disembedding in Parkinson's disease.

Crucian GP, Armaghani S, Armaghani A, Foster PS, Burks DW, Skoblar B, Drago V, Heilman KM.

J Clin Exp Neuropsychol. 2010 Feb;32(2):190-200. doi: 10.1080/13803390902902441.

Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study.

Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Br

Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):220-8. doi: 10.1002/ajmg.b.30980.

Genetic analysis of Parkin in early onset Parkinson's disease (PD): Novel intron 9 g > a single nucleotide polymorphism and risk of Taiwanese PD.

Wu YR, Wu CH, Chao CY, Kuan CC, Zhang WL, Wang CK, Chang CY, Chang YC, Lee-Chen GJ, Chen CM.

Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):229-34. doi: 10.1002/ajmg.b.30977.

Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease.

Mace JL, Porter RJ, Dalrymple-Alford JC, Wesnes KA, Anderson TJ.

J Psychopharmacol. 2010 Oct;24(10):1465-72. doi: 10.1177/0269881109105721.

LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease.

Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, Orr-Urtreger A.

Neurogenetics. 2010 Feb;11(1):121-5. doi: 10.1007/s10048-009-0198-9.

Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosis.

Voss TS, Brocht AF, Ravina B.

Mov Disord. 2010 Jan 15;25(1):124-5. doi: 10.1002/mds.22575. No abstract available.

Evaluation of dementia rating scales in Parkinson's disease dementia.

Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S.

Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):142-8. doi: 10.1177/1533317509333904.

Analysis of the UCHL1 genetic variant in Parkinson's disease among Chinese.

Tan EK, Lu CS, Peng R, Teo YY, Wu-Chou YH, Chen RS, Weng YH, Chen CM, Fung HC, Tan LC, Zhang ZJ, An XK, Lee-Chen GJ, Lee MC, Fook-Chong S, Burgunder JM, Wu RM, Wu YR.

Neurobiol Aging. 2010 Dec;31(12):2194-6. doi: 10.1016/j.neurobiolaging.2008.11.008.

Top-down attentional control in Parkinson's disease: salient considerations.

Cools R, Rogers R, Barker RA, Robbins TW.

J Cogn Neurosci. 2010 May;22(5):848-59. doi: 10.1162/jocn.2009.21227.

[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].

van Laar T, Boon AJ, Bloem BR.

Ned Tijdschr Geneeskd. 2010;154:A2496. Dutch.

The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease.

Rowe JB, Hughes L, Williams-Gray CH, Bishop S, Fallon S, Barker RA, Owen AM.

Neurobiol Aging. 2010 Jun;31(6):1064-8. doi: 10.1016/j.neurobiolaging.2008.07.009.

L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.

Mo J, Zhang H, Yu LP, Sun PH, Jin GZ, Zhen X.

Neurobiol Aging. 2010 Jun;31(6):926-36. doi: 10.1016/j.neurobiolaging.2008.06.017.